Ticker Scorecard - ALLO Basics Company: Allogene Therapeutics, Inc. IPO Date: October 8, 2018 Sector: Healthcare Industry: Biotech Market Cap: $339.67M Activated in VL: True Average Daily Range Avg Daily Range: $0.48 | 3.02% Avg Daily Range (30 D): $0.07 | 3.66% Avg Daily Range (90 D): $0.08 | 3.56% Institutional Daily Volume Avg Daily Volume: 1.29M Avg Daily Volume (30 D): 2.57M Avg Daily Volume (90 D): 2.18M Trade Size Avg Trade Size (Sh.): 121 Avg Trade Size (Sh.) (30 D): 271 Avg Trade Size (Sh.) (90 D): 214 Institutional Trades Total Inst.Trades: 2,845 Avg Inst. Trade: $1.88M Avg Inst. Trade (30 D): $1.56M Avg Inst. Trade (90 D): $1.05M Avg Inst. Trade Volume: .16M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.46M Avg Closing Trade (30 D): $1.85M Avg Closing Trade (90 D): $.97M Avg Closing Volume: 221.53K     News Dec 26, 2024 @ 4:26 PM Oncology in Focus: How Emerging Therapies Are Resh... Source: Prnewswire Oct 22, 2024 @ 5:00 PM Gene Therapy Clinical Trial Pipeline Gains Momentu... Source: Delveinsight Sep 10, 2024 @ 8:51 AM Gene Editing Therapeutics Market Forecast 2024-202... Source: Researchandmarkets.Com Jul 1, 2024 @ 12:30 PM Allogene Therapeutics Activates Three Community Ca... Source: Allogene Therapeutics, Inc. Jun 20, 2024 @ 12:30 PM Allogene Therapeutics Initiates Pivotal Phase 2 Tr... Source: Allogene Therapeutics, Inc. Financials   TTM Q3 2024 Q2 2024 Basic EPS $-1.56 $-.32 $-.35 Diluted EPS $-1.56 $-.32 $-.35 Revenue $ .04M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -283.43M $ -66.29M $ -66.36M Operating Income / Loss $ -297.82M $ -71.77M $ -71.43M Cost of Revenue $ $ $ Net Cash Flow $ -18.01M $ -119.43M $ 119.63M PE Ratio